Semaglutide

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, a class of prescription medications originally developed to treat type 2 diabetes and now widely used for chronic weight management. It is marketed under the brand names Ozempic and Rybelsus for diabetes and Wegovy for obesity, all manufactured by Novo Nordisk.

Structurally, semaglutide is a modified peptide based on the human GLP-1 hormone, sharing about 94% of its amino acid sequence. Two key modifications (a substitution at position 8 to resist enzymatic breakdown and the attachment of a fatty acid chain that binds to albumin) extend its half-life to roughly one week. This allows once-weekly subcutaneous injection (Ozempic, Wegovy) or, in a specially formulated tablet, once-daily oral dosing (Rybelsus).

Semaglutide received FDA approval in 2017 for type 2 diabetes and in 2021 for weight management as Wegovy. Because it belongs to the broader family of GLP-1 medications, understanding the underlying biology is easier with a foundation in how GLP-1 receptor agonists work. This guide reviews the mechanism, the clinical evidence, the safety profile, dosing, and how semaglutide compares to alternatives. This article is for educational purposes only and is not medical advice; consult a qualified healthcare professional before starting any medication.

🧮 Semaglutide Reconstitution Calculator

Semaglutide acts by binding to and activating the GLP-1 receptor, a G protein-coupled receptor found on pancreatic beta cells, in the brainstem and hypothalamus, in the gastrointestinal tract, and in the heart, blood vessels and kidneys. Native GLP-1 is released by intestinal L cells after a meal and is cleared within minutes by the enzyme DPP-4 and by the kidneys. Semaglutide reproduces the action of this hormone but lasts far longer.

Why it lasts about a week. Two structural changes explain the long action. An aminoisobutyric acid (Aib) at position 8 protects the peptide from DPP-4 cleavage, and a C18 fatty diacid attached to lysine 26 through a linker lets the molecule bind reversibly to albumin in the blood. Albumin binding slows kidney clearance and gives an elimination half-life of roughly seven days, which is why the injectable products are given once a week. The oral tablets use a different trick: the absorption enhancer SNAC raises the local pH in the stomach and allows a small fraction of the peptide to cross the stomach wall.

Pancreas. Semaglutide increases insulin secretion and lowers glucagon secretion only when blood glucose is raised. This glucose dependence is the reason why the risk of hypoglycemia is low when it is not combined with insulin or sulfonylureas.

Brain. Labelled semaglutide reaches areas of the hypothalamus and hindbrain that are not fully protected by the blood-brain barrier. Activation of GLP-1 receptors there reduces hunger, increases fullness and lowers the reward value of energy-dense foods. In trials, this reduction in energy intake, not an increase in energy expenditure, explains most of the weight loss.

Stomach and gut. Semaglutide slows gastric emptying, an effect that is strongest in the first weeks of treatment. This contributes to lower post-meal glucose and to the nausea that many people feel early in treatment.

Heart, vessels and kidneys. The reductions in cardiovascular events seen in SELECT and in kidney events seen in FLOW are only partly explained by weight loss and better glucose control. Lower blood pressure, lower inflammatory markers such as CRP and possible direct effects on blood vessels are proposed contributors, but the exact mechanisms are still being studied.

The strongest evidence for semaglutide in obesity comes from the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program. In the landmark STEP 1 trial published in The New England Journal of Medicine, adults with overweight or obesity who received 2.4 mg of semaglutide weekly alongside lifestyle counseling lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% in the placebo group.

Across the STEP program, average weight loss generally falls in the 15-17% range, with a substantial proportion of participants losing 20% or more. Improvements were also seen in waist circumference, blood pressure, lipid profiles, and markers of inflammation.

An important caveat from STEP 4: when semaglutide was discontinued, participants regained much of the lost weight, indicating that the medication addresses the physiology of appetite rather than providing a permanent change. Weight-loss peptides now account for a majority of peptide-related search interest, but durable results still depend on sustained treatment and lifestyle.

How Effective Is It for Type 2 Diabetes?

Semaglutide's original indication was type 2 diabetes, studied in the SUSTAIN trial program. Across these trials, semaglutide produced clinically meaningful reductions in HbA1c (a marker of average blood glucose over three months), typically in the range of 1.0-1.8 percentage points depending on dose and comparator.

In head-to-head trials, semaglutide reduced HbA1c more than several other glucose-lowering therapies, including some other GLP-1 receptor agonists and the SGLT2 inhibitor empagliflozin. It also produced consistent weight reduction, an advantage over insulin and sulfonylureas, which tend to promote weight gain.

• Glycemic control: A high proportion of participants reached target HbA1c below 7%.
• Low hypoglycemia risk: Because insulin release is glucose-dependent, the risk of dangerously low blood sugar is modest when used without insulin or sulfonylureas.
• Weight benefit: Unlike many diabetes drugs, semaglutide reduces body weight, addressing a common comorbidity.

The oral formulation (Rybelsus) offers comparable glycemic benefits for patients who prefer a tablet, though absorption is sensitive to timing and food intake. Treatment decisions should always be individualized by a physician.

Does Semaglutide Protect the Heart?

Beyond glucose and weight, semaglutide has demonstrated cardiovascular benefits. The SELECT trial, published in The New England Journal of Medicine in 2023, enrolled more than 17,000 adults with overweight or obesity and established cardiovascular disease but without diabetes.

Over an average follow-up of about three years, weekly semaglutide reduced the risk of major adverse cardiovascular events (a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke) by 20% compared with placebo. This was the first large trial to show that a GLP-1 medication could lower cardiovascular risk in people with obesity independent of diabetes.

Earlier, the SUSTAIN-6 cardiovascular outcomes trial in people with type 2 diabetes had already shown a significant reduction in cardiovascular events. Together, these findings have reshaped how clinicians view semaglutide: not only as a glucose-lowering or weight-loss agent, but as a therapy with potential to reduce serious cardiovascular complications. As always, these benefits were observed in specific high-risk populations and should not be generalized to everyone.

Like all medications, semaglutide carries risks. The majority of adverse effects are gastrointestinal and tend to be most pronounced when starting treatment or escalating the dose.

• Common (very frequent): nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite. These are usually mild to moderate and often diminish over time.
• Less common: gallstones and gallbladder disease, particularly with rapid weight loss.
• Rare but serious: acute pancreatitis, severe gastrointestinal events, and acute kidney injury (often secondary to dehydration from vomiting).

Semaglutide carries a boxed warning regarding thyroid C-cell tumors, based on rodent studies; it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. It should also be used with caution, or avoided, during pregnancy.

Because semaglutide slows gastric emptying, it can affect the absorption of other oral medications and has implications for anesthesia and surgery, where retained stomach contents raise aspiration risk. Patients should disclose its use before any procedure. Slow dose escalation is the primary strategy to minimize side effects. No medication is "completely safe"; all benefits must be weighed against individual risks with a healthcare provider.

How Is Semaglutide Dosed?

Semaglutide dosing follows a gradual titration schedule designed to improve tolerability by allowing the gut to adapt. The exact regimen differs by brand and indication. The table below summarizes typical approved approaches; actual prescribing is determined by a physician.

For injectable products, treatment generally begins at a low dose (for example, 0.25 mg weekly) and is increased at roughly four-week intervals until the target maintenance dose is reached. This stepwise escalation reduces nausea and other gastrointestinal effects. Injections are administered subcutaneously in the abdomen, thigh, or upper arm.

It is important to distinguish prescribed, pharmaceutical-grade semaglutide from unregulated "research" or compounded products of uncertain purity and dosing. Self-administration of non-prescription semaglutide is not recommended; consult a healthcare professional and use only products obtained through legitimate medical channels.

How Does It Compare to Alternatives?

Semaglutide is part of a rapidly growing class of incretin-based therapies. The most prominent alternative is tirzepatide (Mounjaro for diabetes, Zepbound for weight loss), a dual GIP/GLP-1 receptor agonist. In the SURMOUNT trials, tirzepatide produced average weight loss of roughly 20-22%, and a head-to-head diabetes trial (SURPASS-2) showed greater HbA1c and weight reductions than semaglutide.

Other GLP-1 agonists include liraglutide (a daily injection) and dulaglutide. Choice among these depends on the indication, tolerability, cost, availability, and patient preference. For readers interested in the broader landscape of bioactive peptides used in metabolic and regenerative contexts (from BPC-157 to other commonly discussed peptides), it is worth emphasizing that, unlike most of those compounds, semaglutide and tirzepatide are fully approved, rigorously studied prescription drugs.

Is Semaglutide Legal and Approved?

Yes, semaglutide is an approved prescription medication in the United States, European Union, and many other jurisdictions. The FDA approved it for type 2 diabetes in 2017 and for chronic weight management in 2021; the EMA granted comparable approvals. It is dispensed only with a valid prescription.

However, soaring demand has fueled a market of compounded and "research-use-only" semaglutide products of variable quality. Regulators have issued warnings about counterfeit pens, unverified dosing, and impurities in some compounded or grey-market preparations. Legal status, availability, and the rules around compounding vary by country and can change as supply conditions shift.

For safety, semaglutide should be obtained through licensed pharmacies and used under medical supervision. The athletic implications also matter: anti-doping authorities monitor metabolic agents, so competitive athletes should verify current rules. This guide is educational and not a substitute for professional medical advice; legal status varies by jurisdiction, and you should consult a qualified healthcare provider and follow local regulations. See our medical disclaimer for more information.

Semaglutide is now available in several products whose approved uses differ between the United States and the European Union. The table below summarizes the main indications as of November 2026. It is a simplified overview, not prescribing information: the exact wording, eligible patients and conditions of use are set by each national label.

Two points matter when reading these results. First, the headline numbers come from different analyses: company announcements often quote the result among people who kept taking the drug (for example 16.6% for the Wegovy pill and 20.7% for Wegovy HD), while the peer-reviewed papers report the more conservative intention-to-treat estimates shown above. Second, the higher strength brought more side effects: in STEP UP, gastrointestinal adverse events occurred in 70.8% of participants on 7.2 mg versus 61.2% on 2.4 mg, and dysaesthesia (abnormal skin sensations) in 22.9% versus 6.0%.

The MASH approvals in the US and the EU rest on liver biopsy results at 72 weeks in ESSENCE: resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of participants on semaglutide versus 34.3% on placebo. Both approvals are conditional on the second part of the trial, which is designed to show an effect on clinical liver events.

From 2022 to early 2025, semaglutide injections were on the FDA drug shortage list. During a shortage, US law allows state-licensed pharmacies (section 503A) and outsourcing facilities (section 503B) to compound copies of an approved drug, and a large market of compounded semaglutide grew, often sold through telehealth services.

On 21 February 2025, the FDA declared the semaglutide shortage resolved. It gave compounders a transition period that ended on 22 April 2025 for 503A pharmacies and on 22 May 2025 for 503B outsourcing facilities. Since then, compounders can no longer rely on the shortage to make copies of Ozempic or Wegovy. Compounding for an individual patient whose medical needs cannot be met by the approved product remains possible under strict conditions.

On 30 April 2026, the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, the list of substances that outsourcing facilities may use to compound from bulk ingredients. The agency stated that it had not identified a clinical need for this. The public comment period, first set to close on 29 June 2026, was extended to 30 July 2026; at the time of this update, we have not found a published final decision.

The FDA reminds the public that compounded drugs are not FDA-approved: the agency does not review their safety, effectiveness or quality before they are sold. By 31 May 2026 it had received 990 adverse event reports involving compounded semaglutide, some of them linked to dosing errors.

Semaglutide is not covered by the US HHS enforcement-discretion policy of 28 October 2026. That policy concerns six other peptides only (BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV), compounded by 503A pharmacies under strict conditions. It does not apply to semaglutide, tirzepatide or any other GLP-1 medicine, and semaglutide sold online as a "research chemical" is not a medicine in any jurisdiction.

Semaglutide is one of the most studied medicines of the last decade, but the evidence still has clear limits.

It does not show lasting weight loss after stopping. In the STEP 1 extension, 327 participants were followed for one year after treatment ended. Those who had received semaglutide had lost 17.3% of their body weight at week 68, then regained 11.6 percentage points by week 120, leaving a net loss of 5.6%. Blood pressure, lipid and glucose improvements also moved back toward baseline. The authors concluded that ongoing treatment appears necessary to keep the benefits.

It does not show that all of the weight lost is fat. In a DXA body-composition substudy of STEP 1 (140 participants), total fat mass fell by 19.3% and lean body mass by 9.7% from baseline, so the proportion of lean mass in the body rose but a meaningful amount of lean tissue was lost. In an MRI substudy of STEP UP (55 participants), thigh muscle volume fell by 1.1 L more than with placebo (not statistically significant), while the number of sit-to-stand repetitions was preserved. Whether this lean-mass loss matters for strength and function over many years, especially in older adults, is not known.

It does not show very long-term outcomes. The longest randomized trials followed participants for about three to four years (mean of about 3.3 years in SELECT, median 3.4 years in FLOW, median about 4 years in SOUL). There are no randomized data on decades of use, and data in pregnancy, in adolescents over the long term and in people over 75 remain limited. The MASH approvals rely on liver biopsy improvements, not yet on fewer cirrhosis, transplant or liver deaths.

Rare risks are still being evaluated. In June 2025, the EMA safety committee (PRAC) concluded that non-arteritic anterior ischemic optic neuropathy (NAION), a cause of sudden vision loss in one eye, is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. The signal first came from observational studies such as a 2024 US cohort, which cannot prove causation on their own. For suicidal thoughts, the PRAC concluded in April 2024 that the evidence does not support a causal link with GLP-1 receptor agonists. Pancreatitis, gallbladder disease and aspiration during anesthesia remain known risks that are monitored.

It does not show that trial results transfer directly to daily life. Trial participants received regular visits and lifestyle counseling, and the drugs were supplied. Results with compounded or unregulated products, whose content is not verified, cannot be assumed to match those of the approved medicines.